The article reviews the potential of γδ T cells as cellular vehicles for anti-tumor immunity, highlighting their unique properties and advantages over conventional αβ T cells. γδ T cells, which occupy the interface between innate and adaptive immunity, can detect a wide variety of ligands on transformed host cells and respond by directly eliminating them. They are particularly useful for treating cancers that downregulate HLA class I expression, reducing the risk of graft-versus-host disease (GvHD) and allowing allogeneic use. The article discusses the subtypes of γδ T cells, their ligands, and their roles in cancer prognosis and survival. It also addresses the gaps in knowledge, such as the need to refine γδ T cell subtypes and identify more ligands, and the influence of the tumor microenvironment (TME) on γδ T cell function. The authors review clinical trials involving γδ T cell therapies, noting that while some trials have shown promising results, others have been less successful. They propose strategies to improve the anti-tumor activity and durability of γδ T cells, including ex vivo expansion, genetic engineering, and non-genetic approaches. These strategies aim to enhance the cytotoxicity and specificity of γδ T cells, making them more effective in treating various cancers.The article reviews the potential of γδ T cells as cellular vehicles for anti-tumor immunity, highlighting their unique properties and advantages over conventional αβ T cells. γδ T cells, which occupy the interface between innate and adaptive immunity, can detect a wide variety of ligands on transformed host cells and respond by directly eliminating them. They are particularly useful for treating cancers that downregulate HLA class I expression, reducing the risk of graft-versus-host disease (GvHD) and allowing allogeneic use. The article discusses the subtypes of γδ T cells, their ligands, and their roles in cancer prognosis and survival. It also addresses the gaps in knowledge, such as the need to refine γδ T cell subtypes and identify more ligands, and the influence of the tumor microenvironment (TME) on γδ T cell function. The authors review clinical trials involving γδ T cell therapies, noting that while some trials have shown promising results, others have been less successful. They propose strategies to improve the anti-tumor activity and durability of γδ T cells, including ex vivo expansion, genetic engineering, and non-genetic approaches. These strategies aim to enhance the cytotoxicity and specificity of γδ T cells, making them more effective in treating various cancers.